Clinical Trials
188 trialsSTARTRK-2
Hoffmann-La Roche
PIKALO-1
Eli Lilly and Company
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
Daiichi Sankyo
18F-T2 PET/CT Imaging for CAIX Positive Solid Tumors
Peking University First Hospital
MAGE-A4ᶜ¹º³²T for Multi-Tumor
USWM, LLC (dba US WorldMeds)
Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors
ModeX Therapeutics, An OPKO Health Company
Evaluation of On-Couch CBCT Image Quality
Varian, a Siemens Healthineers Company
Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors
Ensem Therapeutics
Lead-212 PSV359 Therapy for Patients With Solid Tumors
Perspective Therapeutics
Veliparib, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery and Liver or Kidney Dysfunction
National Cancer Institute (NCI)
A Simple Walking Program to Enhance Concurrent Chemoradiotherapy Delivery
Montefiore Medical Center
ADP-A2M4CD8 as Monotherapy or in Combination With Either Nivolumab or Pembrolizumab in HLA-A2+ Subjects With MAGE-A4 Positive Tumors (SURPASS)
USWM, LLC (dba US WorldMeds)
A Study of Disitamab Vedotin in Previously Treated Solid Tumors That Express HER2
Seagen Inc.
A Phase I/II Study of Combination Immunotherapy for Advanced Cancers Including HPV-Associated Malignancies, Small Bowel, and Colon Cancers
National Institutes of Health Clinical Center (CC)
Dose Escalation and Dose Expansion Study of CPO-100 in Patients With Advanced Solid Tumors
Conjupro Biotherapeutics, Inc.
An Imaging Agent (Pafolacianine) for Identifying Lesions in Pediatric Patients With Primary or Metastatic Solid Tumors
Mayo Clinic
Study of DF6215 in Patients With Advanced Solid Tumors
Dragonfly Therapeutics
KETOCOL
Centre Oscar Lambret
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
PMV Pharmaceuticals, Inc
Riluzole For Preventing Cognitive Dysfunction in Ca Pts Receiving Chemo (REFOCUS): Pilot Trial
University of California, Irvine
IDOV-Immune for Advanced Solid Tumors
ViroMissile, Inc.
ONE TEAM
Duke University
TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers
Tizona Therapeutics, Inc
Study of the CDK4/6 Inhibitor Palbociclib (PD-0332991) in Combination With the PI3K/mTOR Inhibitor Gedatolisib (PF-05212384) for Patients With Advanced Squamous Cell Lung, Pancreatic, Head & Neck and Other Solid Tumors
Dana-Farber Cancer Institute
A Study of PARG Inhibitor IDE161 in Participants With Advanced Solid Tumors
IDEAYA Biosciences
Improving Care for Rural Patients With Solid Tumors
University of Colorado, Denver
SCANDARE
Institut Curie
Quality of Life Assessment of Radiotherapy in Recurrent Head and Neck Cancer
University of Oklahoma
A Study to Evaluate Lenti-HPV-07 Immunotherapy Against HPV+ Cervical or Oropharyngeal Cancer
Theravectys S.A.
AKIR001
Karolinska University Hospital
Dose-finding Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of SNB-101(SN-38) in Patients With Tumors
SN BioScience
SL-28 for Advanced Solid Tumours
Second Life Therapeutics
CONFIGURE
Varian, a Siemens Healthineers Company
A Study of Safety and Efficacy of KFA115 Alone and in Combo With Pembrolizumab in Patients With Select Advanced Cancers
Novartis
A Clinical Study of TJ004309 With Atezolizumab (TECENTRIQ®) in Patients With Ovarian Cancer and Selected Solid Tumors
I-Mab Biopharma US Limited
Trop2-targeted immunoPET Imaging of Solid Tumors
RenJi Hospital
Study BT5528-100 in Patients With Advanced Solid Tumors Associated With EphA2 Expression
BicycleTx Limited
A Basket Study of Customized Autologous TCR-T Cell Therapies in Patients With Locally Advanced (Unresectable) or Metastatic Solid Tumors
TScan Therapeutics, Inc.
Study of BDC-3042 as Single Agent and in Combination With Cemiplimab in Patients With Advanced Malignancies
Bolt Biotherapeutics, Inc.
Phase 1/2a Study of SQ3370 in Patients With Advanced Solid Tumors
Shasqi, Inc.
PAVO
Tempus AI
AYAConnect
UNC Lineberger Comprehensive Cancer Center
A Phase 1a/1b Study of ACTM-838 in Patients With Advanced Solid Tumors
Actym Therapeutics, Inc.
IMPROVE
Memorial Sloan Kettering Cancer Center
Phase 1/2 Clinical Trial of CP-506 (HAP) in Monotherapy or With Carboplatin or ICI
Maastricht University Medical Center
A Study to Evaluate TROP2 ADC LCB84 Single Agent and in Combination With an Anti-PD-1 Ab in Advanced Solid Tumors
LigaChem Biosciences, Inc.
DECIDE
Institut Claudius Regaud
A First-in-human Study Using BDC-1001 as a Single Agent and in Combination With Nivolumab in Advanced HER2-Expressing Solid Tumors
Bolt Biotherapeutics, Inc.
EARN
Washington University School of Medicine
GLIMMER-01
Palleon Pharmaceuticals, Inc.